Busaidy N, Konda B, Wei L, Wirth LJ, et al. Dabrafenib vs dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer - results of a randomized, phase 2, open-label, multicenter trial. Thyroid 2022 Jun 4. doi: 10.1089/thy.2022.0115.
PMID: 35658604